Background: Limited French data are available for the different clinical types (paroxysmal, persistent and permanent) of atrial fibrillation and their comorbidities (AF).
Aims: To provide contemporary insights into the characteristics and management of outpatients with a history of or current AF in France.
Methods: EPHA is a national, observational, cross-sectional, multicentre descriptive study with retrospective data collection relating to the management, treatment and hospitalization of patients with AF.
Results: One thousand three hundred and thirty-one patients (mean age: 74 +/- 11 years [55.7% > or =75 years]; 58.8% men) were included into the study between February 2009 and May 2009; their data were collected during the past 12 months. Of these, 38.2% had paroxysmal AF, 10.0% persistent AF and 51.8% permanent AF. Most patients had at least one cardiovascular risk factor (80.8%). Almost all patients (96.6%) had received an antiarrhythmic drug in the previous year, of which 59.6% received a rhythm control strategy (class I, class III) with or without rate control strategy (class II, class IV, digitalis) and 40.6% received a rate control strategy exclusively. Almost all (94.4%) patients were treated with an antithrombotic: 83.4% with a vitamin K antagonist and 21.9% with antiplatelet therapy. Almost one-fifth (18.4%) of patients had been hospitalized related to AF at least once in the previous year. Patients with paroxysmal and persistent AF were hospitalized more frequently (20.0% and 31.1%, respectively) than patients with permanent AF (14.8%).
Conclusions: About half of the patients had paroxysmal or persistent AF. Four-fifths of AF patients had at least one cardiovascular risk factor. The use of antiarrhythmic and antithrombotic treatments was very high. The rhythm control strategy was preferred in patients with paroxysmal or persistent AF.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.acvd.2010.06.001 | DOI Listing |
J Cardiovasc Electrophysiol
January 2025
Department of Electrophysiology, German Heart Center Munich, TUM University Hospital, Munich, Bavaria, Germany.
Introduction: Data regarding safety and long-term outcome of very high-power-short duration (vHPSD) ablation in adult congenital heart disease (ACHD) patients with paroxysmal or persistent atrial fibrillation (AF) are lacking.
Methods: Retrospective observational single-center study. The data of 66 consecutive ACHD patients (mean age 60 ± 12.
Eur Heart J Digit Health
January 2025
Department of Cardiovascular Medicine, Kyorin University, 6-20-2, Shinkawa, Mitaka-city, Tokyo 181-8611, Japan.
Aims: Atrial fibrillation (AF) leads to impaired exercise capacity, and catheter ablation (CA) for AF improves exercise capacity. However, the precise changes in daily activities after CA for AF remain unclear. The authors aimed to evaluate the changes in daily activities following CA for AF using a wristwatch-type pulse wave monitor (PWM), which tracks steps and exercise time, estimates burnt daily calories, and records sleep duration, in addition to establishing the rhythm diagnosis of AF or non-AF.
View Article and Find Full Text PDFEur J Clin Invest
January 2025
Department of Thromboembolic Disorders, Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland.
Background: The role of a prothrombotic state in atrial fibrillation (AF) progression to permanent arrythmia (PerAF) is unclear. Formation of denser and poorly lysable fibrin clots has been observed in AF patients also with sinus rhythm in association with higher stroke risk. We investigated whether altered fibrin clot properties and other prothrombotic state markers may contribute to AF transition to PerAF.
View Article and Find Full Text PDFEuropace
January 2025
Division of Cardiology, McGill University Medical Center, Montreal, Quebec, Canada.
Background: Loss of bipolar electrograms immediately after pulsed field ablation (PFA) makes lesion durability assessment challenging.
Objective: The aim of this trial (NCT06700226) was to evaluate a novel ablation system that can optically predict lesion durability by detecting structural changes in the tissue during ablation.
Methods: Patients with paroxysmal atrial fibrillation underwent pulmonary vein isolation (PVI) using PFA (AblaView®, MedLumics).
Background: Initial clinical studies of pulsed field ablation (PFA) to treat atrial fibrillation (AF) indicated a >90% durability rate of pulmonary vein isolation (PVI). However, these studies were largely conducted in single centers and involved a limited number of operators. The electrophysiological findings and outcomes in patients undergoing repeat ablation after an initial PF ablation for AF are incompletely understood.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!